arrow
R

Robin Cornelissen

erasmus mc cancer institute
H指数:33
被引数:7,769

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

TROP2的归一化膜比作为datopotamab deruxtecan在非小细胞肺癌中预测临床结局的指标

2026-11-110
OAAI
Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study

围手术期纳武利尤单抗(NIVO)对比安慰剂(PBO)用于可切除非小细胞肺癌(NSCLC)患者:来自III期CheckMate 77T研究的临床更新

2024-09-013
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01

Datopotamab deruxtecan (Dato-DXd) 与多西他赛 (DTX) 在伴有脑转移 (mets) 的晚期非鳞状 (NSQ) 非小细胞肺癌 (NSCLC) 患者中的比较:TROPION-Lung01 研究结果

2024-09-010
PRE
Perioperative Nivolumab in Resectable Lung Cancer

可切除肺癌的围手术期Nivolumab

2024-05-1645
PRE
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
2024-04-017
OAAI
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-11-0111
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-10-0128
PRE
CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC

CheckMate 77T: III期研究比较了新辅助nivolumab (NIVO) 加化学疗法 (chemo) 与新辅助安慰剂加化学疗法,然后进行手术和辅助NIVO或安慰剂,用于先前未经治疗的,可切除的IIeIIIb期NSCLC

2023-10-0167
OAAI
Multi-source data approach for personalized outcome prediction in lung cancer screening: update from the NELSON trial

用于肺癌筛查个性化结果预测的多源数据方法: 来自NELSON试验的更新

2023-03-217
OAAI
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

一线nivolumab联合ipilimumab与化疗在不可切除的恶性胸膜间皮瘤患者中的比较: CheckMate 743的3年结果

2022-05-01135
OA